Conatus Pharmaceuticals (CNAT) Gains on WSJ Zika-Related Mention

August 29, 2016 11:58 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Conatus Pharmaceuticals (NASDAQ: CNAT) surges following WSJ mention related to Zika. Shares up 15%.

The article discusses liver-disease drug emricasan for use to quell the Zika virus, which Conatus holds several patents on.


Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment